Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0029463 (
osteosarcoma
)
16,637
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Aflatoxin B1 has been suggested as a causative agent for a G to T mutation at codon 249 in the
p53
gene in human hepatocellular carcinomas from southern Africa and Qidong in China. To test this hypothesis, nine tumors induced by aflatoxin B1 in nonhuman primates were analyzed for mutations in the
p53
gene. These included four hepatocellular carcinomas, two cholangiocarcinomas, a spindle cell carcinoma of the bile duct, a hemangioendothelial sarcoma of the liver, and an
osteogenic sarcoma
of the tibia. None of the tumors showed changes at the third position of codon 249 by cleavage analysis of the HaeIII enzyme site at codon 249. A point mutation was identified in one hepatocellular carcinoma at the second position of codon 175 (G to T transversion) by sequencing analysis of the four conserved domains (II to V) in the
p53
gene. These data suggest that mutations in the
p53
gene are not necessary in aflatoxin B1 induced hepatocarcinogenesis in nonhuman primates. The occurrence of mutation in codon 249 of the
p53
gene in selective samples of human hepatocellular cancers may indicate involvement of environmental carcinogens other than aflatoxin B1 or that hepatitis B virus-related hepatitis is a prerequisite for aflatoxin B1 induction of G to T transversion in codon 249.
...
PMID:Low frequency of p53 gene mutation in tumors induced by aflatoxin B1 in nonhuman primates. 131 Jun 37
A patient with bilateral retinoblastoma and subsequent multiple primary osteosarcomas has been described previously.
Osteosarcoma
cell lines established from this patient were shown to express a shortened RB1 mRNA transcript and no detectable normal Rb protein. We now show that the
osteosarcoma
cell lines have lost one
TP53
allele and contain a mutation in exon 8 codon 286 [GAA to AAA (Glu to Lys)] in the remaining allele. Consequently, the
osteosarcoma
cell lines have no normal Rb protein and no normal
p53 protein
. Neither constitutional DNA nor DNA extracted from a retinoblastoma of the left eye of the patient contained the
TP53
mutation, suggesting that the
TP53
mutation in the
osteosarcoma
cells may represent a tumor-promoting mutation, which confers a selective growth advantage. If both RB1 and
TP53
are involved in the initiation of
osteosarcoma
, the mechanisms for development of the retinoblastoma and
osteosarcoma
tumors are different.
...
PMID:A TP53 mutation detected in cells established from an osteosarcoma, but not in the retinoblastoma of a patient with bilateral retinoblastoma and multiple primary osteosarcomas. 133 9
Multifocal
osteogenic sarcoma
patients without familial histories of increased tumor predisposition were examined for mutations in the highly conserved regions of the
p53
gene.
p53
point mutations were found in tumor DNA from each of the four patients we examined. A germ-line
p53
mutation was detected in one of these patients, and a further rearrangement of the residual wild-type allele was detected in tumor tissue.
p53
germ-line mutations can contribute to the enhanced predisposition to tumor development manifest in patients with multifocal
osteosarcoma
.
...
PMID:Germ-line and somatic p53 gene mutations in multifocal osteogenic sarcoma. 134 75
A malignant stromal tumor of the testis with an
osteosarcoma
component and five of its metastases mainly containing
osteosarcoma
have been analyzed for RB1 and
TP53
abnormalities. Whereas in the primary tumor and in some of the metastases loss of heterozygosity could not be detected for RB1 or for the 17p13 region in which
TP53
is located, other metastases showed such losses of heterozygosity. By polymerase chain reaction analysis an 18-base pair deletion from exon 5 of the
TP53
gene was found in a small proportion of primary tumor cells and in one of the metastases, but not in the other metastases. Therefore, in this case neither RB1 nor
TP53
seems to play an essential role in the initiation of
osteosarcoma
.
...
PMID:Analysis of a metastasizing testicular mixed gonadal stromal tumor with osteosarcoma components suggests that a malignant tumor with the histology of osteosarcoma may develop without primary involvement of RB1 and TP53. 142 18
We studied the pedigrees of 17 index patients with
osteosarcoma
, recording malignant disease and cause of death for first- and second-degree relatives. There were seven cancers and five cancer deaths per 2151.5 person-years in first-degree relatives of
osteosarcoma
patients under the age of 50 years, a significantly greater incidence than in an age- and sex-matched population group (p < 0.001). This excess of malignancy was largely due to two families which fulfilled the criteria for the Li-Fraumeni cancer family syndrome. Both of these families were shown to have the genetic alterations in the
p53
gene which have been implicated in this syndrome. Our study suggests that orthopaedic surgeons seeing new cases of
osteosarcoma
should arrange screening for familial malignancy.
...
PMID:A significant proportion of patients with osteosarcoma may belong to Li-Fraumeni cancer families. 144 51
We analyzed 14 native
osteosarcoma
tissue samples for alterations of the tumor suppressor genes RB1 and
p53
on the DNA level, and as far as possible, the RNA level. Southern blot analyses concerning both tumor suppressor genes were carried out in all osteosarcomas. In two cases we could demonstrate a deletion within the RB1 gene. DNA analysis of a third
osteosarcoma
patient revealed a rearrangement of the
p53
gene. We had the opportunity of performing corresponding northern analyses in eight native
osteosarcoma
specimens. The RB1 gene expression was significantly decreased or completely absent in six tumor samples. In two of these tissue probes the expression of both tumor suppressor genes was missing. We determined coexistence of decreased expression of both tumor suppressor genes in one additional case. In summary, 7/14 or 6/8 cases of osteosarcomas (including only those cases which allowed both analyses) showed RB1 gene alteration. In 3/14 or 3/8 osteosarcomas we could determine
p53
gene abnormalities. This may indicate that either loss of
p53
function is etiologically important only for the development of some osteosarcomas, or a major part of
p53
gene mutations are subtle ones and their detection requires more sophisticated techniques, which are currently under development.
...
PMID:Studies of the RB1 gene and the p53 gene in human osteosarcomas. 152 85
81 candidate families with a rare genetic susceptibility to cancer called Li-Fraumeni syndrome were enrolled in an International Working Group. Review of 2,261 blood relatives revealed a total of 515 family members (23%) who had at least one confirmed cancer diagnosis. The major features of the syndrome, breast cancer, sarcomas of soft tissue and bone, brain tumour, leukemia and adrenal cortical carcinoma accounted for 74% of all the cancers recorded. 64% of all malignant tumours occurred before the age of 45 years. Among females, breast cancer accounted for 43 percent of all cases. There were 22 cases of bilateral metachronous breast cancer. Excluding individuals with bilateral breast cancer, 76 patients developed a second neoplasm, the most common being
osteogenic sarcoma
. The present study agrees with previous reports on the epidemiological aspects of Li-Fraumeni syndrome, the genetic defect of which has recently been found to involve the tumour-suppressor gene
p53
.
...
PMID:[Li-Fraumeni syndrome and the p53 gene]. 155 56
We have investigated the involvement of tumor suppressor genes in the genesis of
osteosarcoma
by analyzing allele losses at polymorphic loci in tumor tissues. Genotypes of DNA from primary
osteosarcoma
tissue and corresponding normal cells from 37 patients were analyzed at 58 polymorphic loci representing each autosomal chromosome arm except 5p and 20q. Allele losses were found at polymorphic loci on 36 of 37 chromosome arms analyzed. In particular, four of them showed frequencies of allele loss higher than 60%: 3q (75%); 13q (68%); 17p (72%); and 18q (64%). This result suggests that, in addition to the RB (retinoblastoma) gene on 13q and the
p53
gene on 17p, at least two more tumor suppressor genes located on 3q and 18q are frequently involved in the development of
osteosarcoma
. The extent of allele losses as defined by fractional allelic loss among 36 tumors was diverse, from 0 to 0.64. The median fractional allelic loss value of 0.32 was much higher than those previously reported in colorectal carcinoma and breast carcinoma. Although no definite association of fractional allelic loss value to clinical prognosis of each case was found in
osteosarcoma
, tumors with 17p loss were more prone to the early onset of lung metastasis than tumors without 17p loss, indicating that allele loss on chromosome 17p can be a useful measure of prognosis.
...
PMID:Allelotype analysis in osteosarcomas: frequent allele loss on 3q, 13q, 17p, and 18q. 156 11
Osteosarcoma
tumorigenesis is consistent with a model by which tumorigenesis results if both alleles at the retinoblastoma susceptibility locus (RBI) are altered. Additional genetic evidence strongly suggests that another obligate event in
osteosarcoma
tumorigenesis is the homozygous alteration of another gene,
p53
. Both the RB1 gene and
p53
have been proposed to act as tumor-suppressor genes, suggesting that, in this instance, tumorigenesis is the result of the loss of gene function of these two genes, rather than a gain of function.
...
PMID:Molecular genetic considerations in osteosarcoma. 167 82
We examined structure and expression of the
p53
and Rb genes in a C3HOS transplantable mouse model of
osteosarcoma
. The results were compared to analogous studies conducted with five human
osteosarcoma
cell lines. The
p53
gene was found rearranged in the mouse tumour. The rearrangement mapped to the first intron region of the
p53
gene and as a result, no
p53
expression could be detected in C3HOS tumours. Using
p53
genomic probes, we have detected the same rearrangement in the original radiation-induced tumour and the various clones that were isolated from it. Deletion and rearrangement of the
p53
gene were also found in three out of five of the human
osteosarcoma
cell lines (MG-63, G-292, Saos-2). No
p53
expression could be detected in these three cell lines. In the affected human
osteosarcoma
cell lines, the rearrangement involved the first intron region. In addition, the mouse tumor was analysed for structural and expression changes in the Rb and the c-myc genes. Normal expression of both genes were detected in the murine tumour. Only one (Saos-2) human
osteosarcoma
cell line exhibited gross structural alteration in the retinoblastoma gene. The results suggest that the inactivation of
p53
may be an important step in the development of osteosarcomas, and that a rearrangement affecting the first intron is common in osteosarcomas.
...
PMID:Inactivation of p53 gene in human and murine osteosarcoma cells. 173 19
1
2
3
4
5
6
7
8
9
10
Next >>